Eli Lilly and Company (NYSE:LLY) Stock Holdings Cut by Snider Financial Group

Snider Financial Group lowered its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,201 shares of the company’s stock after selling 155 shares during the quarter. Eli Lilly and Company comprises 3.0% of Snider Financial Group’s portfolio, making the stock its 10th biggest holding. Snider Financial Group’s holdings in Eli Lilly and Company were worth $6,529,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in LLY. Simon Quick Advisors LLC boosted its holdings in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the period. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $363,000. Liontrust Investment Partners LLP bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $8,326,000. WASHINGTON TRUST Co raised its position in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after acquiring an additional 2,671 shares in the last quarter. Finally, Armstrong Fleming & Moore Inc bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth $357,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 195,055 shares of company stock worth $125,254,657 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $689.52.

Read Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

LLY traded down $20.66 during trading on Monday, hitting $757.30. The company’s stock had a trading volume of 1,589,989 shares, compared to its average volume of 3,206,957. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $342.30 and a twelve month high of $800.78. The business’s fifty day simple moving average is $737.05 and its 200 day simple moving average is $639.82. The firm has a market capitalization of $719.56 billion, a price-to-earnings ratio of 130.69, a P/E/G ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the company earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.